Skip to main content
Premium Trial:

Request an Annual Quote

GenTel, Abnova to Co-develop Custom Immunoassays

NEW YORK, Nov. 9 (GenomeWeb News) - Gentel will combine its custom multiplex immunoassay development service with Abnova's high-throughput protein and antibody content-manufacturing capabilities, Gentel Biosurfaces said today.

 

GenTel's PATH Protein MicroArray System is based on ultra-thin nitrocellulose surface chemistry developed specifically for antibody arrays.

 

GenTel, which is privately held, will develop and offer multiplex immunoassays using protein content from Abnova, the company said.

 

Taiwan-based Abnova specializes in high throughput, in vitro wheat germ protein expression and monoclonal antibody production.

 

Financial details were not disclosed.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.